Gregory Stark, MD
Pulmonary Disease · Ashland, KYNPI 1962500967
Payments from drug & device makers
Across 316 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Genentech USA, Inc.$555
- Novartis$534
- Boehringer Ingelheim$376
- Takeda Pharmaceuticals U.S.A., Inc.$264
- Mylan Specialty L.p.$259
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,72899%
- Education$381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 106 | $1,908 |
| Genentech USA, Inc. | 34 | $555 |
| Novartis | 26 | $534 |
| Boehringer Ingelheim | 23 | $376 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $264 |
| Mylan Specialty L.p. | 9 | $259 |
| Actelion Pharmaceuticals US, Inc. | 9 | $202 |
| Electromed, Inc. | 11 | $168 |
| AstraZeneca | 13 | $164 |
| Grifols USA, LLC | 8 | $156 |
| Jazz Pharmaceuticals Inc. | 8 | $152 |
| Sanofi | 7 | $133 |
| United Therapeutics Corporation | 8 | $118 |
| Pulmonx Corporation | 2 | $95 |
| Sunovion Pharmaceuticals Inc. | 7 | $93 |
| Johnson & Johnson | 6 | $92 |
| Regeneron Healthcare Solutions, Inc. | 3 | $80 |
| Philips North America LLC | 3 | $66 |
| Axsome Therapeutics, Inc. | 3 | $63 |
| Sanofi Pasteur Inc. | 3 | $62 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $44 |
| Medical Graphics Corporation | 1 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Paratek Pharmaceuticals, Inc. | 2 | $26 |
| Merck | 1 | $25 |
| Shire North American Group Inc | 2 | $25 |
| Bayer | 1 | $12 |
How this compares
$5,766 in reported general payments places this provider in the 50th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 123 | $100,653 |
| Fasenra PenBenralizumab | 15 | $90,323 |
| SunosiSolriamfetol Hcl | 16 | $13,390 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $9,562 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $7,754 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $6,183 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 115 | $4,601 |
| Theophylline ErTheophylline Anhydrous | 11 | $2,327 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $2,308 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $1,892 |
| Ventolin HfaAlbuterol Sulfate | 13 | $1,732 |
| Armodafinil | 14 | $1,552 |
| Ipratropium Bromide | 12 | $464 |
| Roflumilast | 12 | $448 |
| Montelukast Sodium | 19 | $139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,908 | $110,216139 claims |
| Axsome Therapeutics, Inc.Sunosi | $63 | $13,39016 claims |
| Boehringer IngelheimCombivent Respimat | $376 | $7,75416 claims |
| AstraZenecaBreztri Aerosphere | $164 | $6,18312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Ashland
- Sana GhalibAshland$16K
- Sabrina RobertsAshland$15K
- Scott NelsonAshland$12K
- Mena ShehataAshland$11K
- John McConnellLouisville$3.5M
- Girish NairLexington$852K
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Firas KouraGeorgetown$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.